Sophiris Bio Inc  

(Public, NASDAQ:SPHS)   Watch this stock  
Find more results for PINK:PTXRF
2.05
-0.02 (-1.12%)
Real-time:   11:13AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.03 - 2.12
52 week 1.83 - 8.55
Open 2.11
Vol / Avg. 66,232.00/237,186.00
Mkt cap 62.33M
P/E     -
Div/yield     -
EPS -0.45
Shares 30.11M
Beta 2.13
Inst. own     -
Aug 7, 2017
Q2 2017 Sophiris Bio Inc Earnings Release (Estimated) Add to calendar
May 15, 2017
Q1 2017 Sophiris Bio Inc Earnings Release
More events from DailyFinance »    

Address

1258 Prospect Street
LA JOLLA, CA 92037
United States - Map
+1-858-7771760 (Phone)
+1-858-4125693 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Sophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer.

Officers and directors

Lars Ekman M.D., Ph.D. Executive Chairman of the Board
Randall E. Woods President, Chief Executive Officer, Director
Peter T. Slover CPA Chief Financial Officer
Allison J. Hulme Ph.D. Chief Operating Officer, Head - Research & Development
Iain R. Mant Corporate Secretary
Joseph L. Turner Jr. Director
Age: 61
John Geltosky Ph.D. Independent Director
James Heppell Independent Director
William R. Rohn Independent Director
Age: 69